JP2012513589A - 骨髄イメージング剤としての99mTc−ペプチド系化合物の応用 - Google Patents
骨髄イメージング剤としての99mTc−ペプチド系化合物の応用 Download PDFInfo
- Publication number
- JP2012513589A JP2012513589A JP2011542321A JP2011542321A JP2012513589A JP 2012513589 A JP2012513589 A JP 2012513589A JP 2011542321 A JP2011542321 A JP 2011542321A JP 2011542321 A JP2011542321 A JP 2011542321A JP 2012513589 A JP2012513589 A JP 2012513589A
- Authority
- JP
- Japan
- Prior art keywords
- bone marrow
- αvβ3 integrin
- marrow tissue
- tissue
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
【選択図】なし
Description
臨床試験における欠陥骨髄組織の検出
以下の臨床試験は、正常骨髄と欠陥骨髄とを識別するためにαvβ3インテグリンの発現を使用することの改善された感度及び特異性を立証するために実施される。主たる最終目標は診断の正確さである。患者は積極的な患者集団から採用される。管理アルゴリズムは、通例、臨床経験、放射線学的外観、外観の変化速度、及び患者の好みに基づいている。管理の誘導を支援するために使用される他の試験としては、CTコントラスト増強、骨髄吸引、生検及び放射性核種骨髄イメージングをはじめとしていくつかの方法が存在している。
本発明は、本明細書に記載された特定の実施形態によって技術的範囲が限定されるべきでない。実際、本明細書に記載されたものに加えて、当業者には本発明の様々な変更態様が上述の説明及び添付の図面から明らかとなろう。かかる変更態様は添付の特許請求の範囲内に含まれるものとする。
Claims (14)
- 骨髄組織の異常を評価するための方法であって、当該方法は前記骨髄組織又は細胞がαvβ3インテグリンポリペプチドを発現しているか否かを判定する段階を含んでなり、前記αvβ3インテグリンポリペプチドを発現していることは前記骨髄が異常であることを表し、前記αvβ3インテグリンポリペプチドをほとんど又は全く発現していないことは前記骨髄が正常であることを表す、方法。
- 前記骨髄組織がヒトの骨髄組織である、請求項1記載の方法。
- 前記判定段階が、前記αvβ3インテグリンポリペプチドとの結合能力を有する標識分子に骨髄組織を接触させることを含む、請求項1記載の方法。
- 前記標的分子が抗体である、請求項3記載の方法。
- 前記標識分子がRGDペプチドである、請求項3記載の方法。
- 前記標識分子が99mTc−NC−100692である、請求項3記載の方法。
- 前記標識分子が骨髄組織を有する哺乳動物に投与される、請求項3記載の方法。
- 骨髄組織を評価するための方法であって、当該方法は前記骨髄組織にαvβ3インテグリンポリペプチドの発現が欠如しているか否かを判定する段階を含んでなり、前記αvβ3インテグリンポリペプチドの発現の欠如は前記骨髄が正常であることを表す、方法。
- 前記骨髄組織がヒトの骨髄組織である、請求項8記載の方法。
- 前記判定段階が、前記αvβ3インテグリンポリペプチドとの結合能力を有する標識分子に前記骨髄組織を接触させることを含む、請求項8記載の方法。
- 前記標的分子が抗体である、請求項10記載の方法。
- 前記標識分子がRGDペプチドである、請求項10記載の方法。
- 前記標識分子が99mTc−NC−100692である、請求項10記載の方法。
- 前記標識分子が骨髄組織を有する哺乳動物に投与される、請求項10記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14019408P | 2008-12-23 | 2008-12-23 | |
US61/140,194 | 2008-12-23 | ||
PCT/US2009/067987 WO2010075058A1 (en) | 2008-12-23 | 2009-12-15 | Application of 99mtc peptide-based compound as a bone marrow imaging agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012513589A true JP2012513589A (ja) | 2012-06-14 |
JP2012513589A5 JP2012513589A5 (ja) | 2012-12-27 |
Family
ID=42035574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011542321A Pending JP2012513589A (ja) | 2008-12-23 | 2009-12-15 | 骨髄イメージング剤としての99mTc−ペプチド系化合物の応用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110256055A1 (ja) |
EP (1) | EP2374002A1 (ja) |
JP (1) | JP2012513589A (ja) |
CN (1) | CN102265158A (ja) |
WO (1) | WO2010075058A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082191A1 (en) * | 2009-12-30 | 2011-07-07 | Ge Healthcare Limited | Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07505528A (ja) * | 1992-04-03 | 1995-06-22 | ジェネンテク,インコーポレイテッド | αvβ3インテグリンに対する抗体 |
JP2007501014A (ja) * | 2003-08-05 | 2007-01-25 | ウイスコンシン アラムニ リサーチ ファンデーション | 化学療法剤の送達のための標的化されたキャリア融合物 |
JP2008298654A (ja) * | 2007-05-30 | 2008-12-11 | Ventana Medical Systems Inc | バイオマーカーの多色発色検出 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE901736L (en) | 1989-05-17 | 1990-11-17 | Fuller H B Licensing Financ | Polypeptide-antibody conjugate for inhibiting cell adhesion |
UA43823C2 (uk) | 1992-07-06 | 2002-01-15 | Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
CA2754102C (en) | 1995-08-14 | 2012-12-18 | The Scripps Research Institute | Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis |
EP0876611A1 (en) | 1995-09-11 | 1998-11-11 | La Jolla Cancer Research Foundation | Molecules that home to a selected organ or tissue in vivo and methods of identifying same |
JP2001501600A (ja) | 1996-09-10 | 2001-02-06 | ザ バーナム インスティテュート | 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法 |
GB9708265D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
CA2291323A1 (en) | 1997-05-28 | 1998-12-03 | Genvec, Inc. | Alternatively targeted adenovirus |
GB9711115D0 (en) | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
US7297542B2 (en) | 1998-02-06 | 2007-11-20 | The Uab Research Foundation | Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob |
AU2662999A (en) | 1998-02-09 | 1999-08-23 | Genzyme Corporation | Nucleic acid delivery vehicles |
US6294320B1 (en) * | 1998-12-04 | 2001-09-25 | Barnes-Jewish Hospital | Cell matrix plaques of initial bone formation |
-
2009
- 2009-12-15 JP JP2011542321A patent/JP2012513589A/ja active Pending
- 2009-12-15 US US13/141,339 patent/US20110256055A1/en not_active Abandoned
- 2009-12-15 EP EP09793406A patent/EP2374002A1/en not_active Withdrawn
- 2009-12-15 WO PCT/US2009/067987 patent/WO2010075058A1/en active Application Filing
- 2009-12-15 CN CN2009801528163A patent/CN102265158A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07505528A (ja) * | 1992-04-03 | 1995-06-22 | ジェネンテク,インコーポレイテッド | αvβ3インテグリンに対する抗体 |
JP2007501014A (ja) * | 2003-08-05 | 2007-01-25 | ウイスコンシン アラムニ リサーチ ファンデーション | 化学療法剤の送達のための標的化されたキャリア融合物 |
JP2008298654A (ja) * | 2007-05-30 | 2008-12-11 | Ventana Medical Systems Inc | バイオマーカーの多色発色検出 |
Non-Patent Citations (3)
Title |
---|
JPN5012006589; BECKER PAMELA S: 'INHIBITION OF alpha(V)beta(3) INTEGRIN DISRUPTS ADHESION AND ENHANCES CHEMOTHERAPY EFFECT IN MULTIPLE MYE' BLOOD V110 N11 PT2, 200711, P275B * |
JPN5012006592; HUA JING: 'NONINVASIVE IMAGING OF ANGIOGENESIS WITH A TC-99M-LABELED PEPTIDE TARGETED AT alpha(V)beta(3) INTEGRIN AF' CIRCULATION V111 N24, 200506, P3255-3260 * |
JPN5012006593; OULIE: 'QUANTIFICATION OF NC100692, A NEW TRACER FOR <99M>TC-IMAGING OF ANGIOGENESIS, IN HUMAN PLASMA USING' JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS V852 N1-2, 20070531, P605-610, ELSEVIER * |
Also Published As
Publication number | Publication date |
---|---|
CN102265158A (zh) | 2011-11-30 |
WO2010075058A1 (en) | 2010-07-01 |
US20110256055A1 (en) | 2011-10-20 |
EP2374002A1 (en) | 2011-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues | |
Beer et al. | PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis | |
Sahni et al. | Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation | |
Zhu et al. | 99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging | |
Gu et al. | Characterization of Bone Marrow Laminins and Identification of 5-Containing Laminins as Adhesive Proteins for Multipotent Hematopoietic FDCP-Mix Cells | |
Konstantinides et al. | Distinct antithrombotic consequences of platelet glycoprotein Ibα and VI deficiency in a mouse model of arterial thrombosis | |
Sancey et al. | In vivo imaging of tumour angiogenesis in mice with the α v β 3 integrin-targeted tracer 99m Tc-RAFT-RGD | |
Weber et al. | Neutrophil-derived JAML inhibits repair of intestinal epithelial injury during acute inflammation | |
Odrljin et al. | Heparin-binding domain of fibrin mediates its binding to endothelial cells | |
Shida et al. | Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation | |
Dijkgraaf et al. | Radionuclide imaging of tumor angiogenesis | |
Karsdal et al. | Profiling and targeting connective tissue remodeling in autoimmunity-a novel paradigm for diagnosing and treating chronic diseases | |
Baart et al. | Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer | |
Niu et al. | PET imaging of angiogenesis | |
Zannetti et al. | Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with αvβ5 | |
Karsdal et al. | Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes | |
ES2307333T3 (es) | Receptor del activador del plasminogeno tipo urocinasa como diana para el diagnostico de micrometastasis. | |
JP6018585B2 (ja) | 心血管イメージングに関連する材料および方法 | |
Luo et al. | An integrin alpha 6-targeted radiotracer with improved receptor binding affinity and tumor uptake | |
Dobrucki et al. | Cardiovascular molecular imaging | |
Alhalhooly et al. | Single-Molecule Force Probing of RGD-Binding Integrins on Pancreatic Cancer Cells | |
JP5317475B2 (ja) | 肝細胞増殖因子受容体が関与する疾患の診断薬及び治療薬 | |
Spessotto et al. | Laminin isoforms 8 and 10 are primary components of the subendothelial basement membrane promoting interaction with neoplastic lymphocytes | |
JP2012513589A (ja) | 骨髄イメージング剤としての99mTc−ペプチド系化合物の応用 | |
Tekabe et al. | Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121106 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130430 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131001 |